Try our Advanced Search for more refined results
Life Sciences - June, 2014
313 articles
- 11th Circ. Affirms Ex-Stiefel Worker's $1.5M Award
- Judge OKs $24.3M In Attys' Fees In Pfizer Pay-For-Delay Row
- Actavis, Forest Labs Give Up 4 Generics In FTC Settlement
- Supreme Court Won't Hear Teva Case Over CAFA Removals
- Bingham Snags Trio of Life Science Pros From Cooley
- Government Says Novartis Can't Escape FCA Kickback Suit
- Deals Rumor Mill: KKR, AbbVie, Fiat Chrysler
- Allergan Says Valeant Valuation Of New Eye Drug Falls Short
- Masimo Rival Didn't Own Blood-Testing Patent, Judge Says
- High Court Declines Damages Case Over Child Vaccine Death
- High Court Sends Amgen Stock-Drop Suit Back To 9th Circ.
- Pfizer Wins Exclusion Of Professor's Report In Zoloft MDL
- Justices Want SG's Take On Generic-Drug Labeling Case
- Making Denver An IP Hub: Benefits Of New USPTO Office
- Ex-SAC Trader Martoma Should Get Over 8 Years: Prosecutors
- Calif. Appeals Court Nixes Bristol-Myers Win In Kickback Row
- Ranbaxy Wins FDA Approval To Sell Generic Diovan
- Medicare Part D Prior Authorizations Come Under Fire
- Troutman Sanders Snags Seasoned Greenberg Traurig IP Atty
- 6th Circ. Spurns Novel Attack On Drugmakers In Darvocet MDL
- Halfway Into 2014, Pharma M&A Still Booming
- 23andMe Customers Ordered To Arbitrate False Ad Claims
- Allergan, Pershing Settle Suit Over Poison Pill
- Takeda, Lilly Say Prejudice Infected $9B Actos Verdict
- 4 Things Every Law Firm Should Do Upon A Cyberbreach
- Preemption Pendulum: Medical Products And Parallel Claims
- Sens. Urge Watchdogs To Inspect $53B Valeant-Allergan Play
- A Look At HHS' Newly Proposed Exclusion Rule: Part 2
- Merz Pays $600M For Ultrasound Facelift Co. Ulthera
- Pfizer Seeks Limits On Tylenol Order In Advil Ad Suit
- Surviving FCA Claims In Novartis Kickback Row To Stay Put
- Del. Judge Trims Unilife Investors' Claims Over Director Pay
- Newest Valeant Ally Plays Up Investor Muscle In M&A Fights
- CORRECTED: Omnicare Seals End To Insurer's FCA Suit
- PhRMA, AHA Urge Supreme Court To Curb FCA Penalties
- Europe Not The Only Inversion Destination For Deal Makers
- A Look At HHS' Newly Proposed Exclusion Rule: Part 1
- 5 Things To Know About FDA Response To Off-Label Petition
- Lessons From Luxembourg V. Genzyme
- J&J Wins Investor Suit Over Ex-CEO's $30M Salary
- ABA, IPO Call For More Claim Construction Deference
- FDA Warns Of Severe Side Effects In Popular Acne Products
- 9 Takeaways From Enforcers On Medicare Fraud Priorities
- Drug Challenged Under AIA Biz Method Review For 1st Time
- AbbVie, Shire Poised For M&A Battle As Tensions Flare
- Mass. Gov. Signs Biologic Substitution Bill Into Law
- SLK Expands Its Tampa IP Practice With Two New Hires
- Texas Attorney Can't Collect Fen-Phen Referral Judgment
- Otsuka Sues To Block Intas' Generic Abilify
- Medtronic Inversion Could Shave $4.2B Off Tax Load
- 6 Objectives China Has Set For Itself On Pediatric Drugs
- Valeant Takes Another Step Toward $53B Allergan Deal
- Goodwin Procter Adds Capital Markets Expert To NY Office
- Burned By MDL Judge, Takeda Finds Hope In State Courts
- Del. Court Sides With Alvogen In Novartis Patent Row
- FDA Issues Final Guidances On Nanotech In Food, Cosmetics
- GSK Blasts Teva's Use Of Pom Ruling To Nix False-Ad Suit
- NY's Muddled Medical Pot Bill Making Investors Paranoid
- Ex-Mylan VP Says He Was Axed Over Cephalon Whistleblowing
- Warning, Warranty Claims Cut From Ortho Birth Control Case
- 9th Circ. Stands By New GSK Trial After Gay Juror Ousting
- Niaspan Antitrust Injury Is 'Pure Speculation,' Judge Told
- Endo's $600M DAVA Deal Provides Case Study In Pharma M&A
- Medicare Supplier's Contract Breach Suit Gets Trimmed
- Two Whistleblowers Cut Out Of $193M Endo Settlement
- FDA Warns GSK Over Flu Vaccine Contamination
- Deals Rumor Mill: Ten Network, Loral, Scripps
- Avanir Sues Ranbaxy To Block Generic Nuedexta
- Provigil Judge Nixes Conspiracy Claims In Antitrust Suit
- Merck Supplement Patents Nixed In 1st Pharma AIA Reviews
- Fed Circ. Says Nordic's 'Children's DHA' Mark Is Generic
- Justices Won't Examine Preemption In Medtronic Injury Case
- FDA Balks At Black Box Warnings On Cholesterol Drugs
- Deals Rumor Mill: Shire, Monsanto, Lululemon
- FDA Ups Ante On Drug Inspections With Detention Authority
- Dentons Nabs Life Sciences Patent Ace For Houston Office
- Allergan Rejects Hostile $53B Bid From Valeant, Ackman
- Zoll Can't Use Double-Patenting Defense In Philips IP Spat
- 3 Lingering Questions About How Actavis Works
- 3rd Circ. Kills Cobalis Suit Over Hedge Fund Scheme
- 5 Ways To Contain The Chaos Of Mass Torts And MDLs
- High Court Told 'Public Use' Rule Nixes Pronova Patent
- Endo, Impax Nailed With New Generic Opana Antitrust Suit
- Dolly Creators Ask Fed. Circ. To Rethink Clone Patent Ruling
- Takeda Destroyed Evidence In $9B Cancer Suit, Judge Says
- Fed. Circ. Won't Revive UV Sterilization Patent Case
- FDA Loosens Grip In Latest Win For Digital Health Firms
- Drug Software Co. Can't Duck Warning Suit On Appeal
- Medtronic Leverages PR To Head Off Inversion Doubts
- Sanofi Chemo Drug May Make Patients Feel Drunk, FDA Says
- Shire Rejects AbbVie's $46B Offer In Latest Inversion Try
- Natrol Avoids False-Ad Class Action Over Enhancement Claims
- FDA Strengthens Blood Clot Warnings On Testosterone Drugs
- Reed Smith Adds 5 K&L Gates Product Liability Partners
- New FDA Database May Have Negative Consequences
- K&L Gates Patent Ace Joins IP Firm Lee & Hayes In Seattle
- Teva Urges 9th Circ. Panel To Keep Pain Med Suits Federal
- Bankrupt Natrol Can Pay Employees, But Trustee Bid Looms
- FTC Warns REMS Abuse Not Safe From Antitrust Law
- Purchasers Blast Wyeth's Immunity Bid In Pay-For-Delay Suit
- Chancery Fast-Tracks Ackman Suit Over Allergan Poison Pill
- 3rd Circ. Decision Deepens Split On Crucial FCA Rule
- Cuomo Hashes Out Medical Marijuana Deal With NY Pols
- US Says Fed. Circ. Must Show Claim Construction Deference
- Novartis Hits Mylan With Patent Suit Over Dementia Patch
- Philly Risperdal Plaintiffs Slam J&J Push For Time Bar
- Female Powerbrokers Q&A: Williams Mullen's McCarroll
- Smartphone Forensics: Tips From The E-Discovery Trenches
- UK-Based LLP Partners Now Enjoy More Protections
- Prioritize When Deposing Plaintiff 'FDA Experts'
- Where Pay-For-Delay Stands One Year After Actavis
- Chancery Won't Halt $658M Bid For Chelsea Therapeutics
- Judge Sides With Novartis In Dementia Patch Patent Row
- Scotland's Health Secretary Seeks Mesh Implant Suspension
- FDA Slaps Apotex Over Data Misconduct In India
- Masuda Funai Snags Patent Pro From Jenner & Block
- 9th Circ. Affirms Wyeth, Schwarz Wins In Nausea Med Row
- HHS Keeps 340B Orphan Drug Policy Despite Court Ruling
- Bayer Nabs $14.2B In Financing To Back Merck Deal
- Porter Wright Nets Diverse Squire Sanders Litigator In Ohio
- Female Powerbrokers Q&A: Bush Seyferth's Cheryl Bush
- Female Powerbrokers Q&A: Davis Wright's Kelli Sager
- Valeant Makes Good On Threat Of Hostile $53B Allergan Play
- USPTO Sets New Rules On Patent Terms After Novartis Ruling
- Merck Defeats Bellwether Case In Fosamax Femur-Injury MDL
- Patient Claims Genzyme Swapped Good Medicine For Bad
- FDA Social Media Guidance Gives Drug Promos An Opening
- Faster FDA Approval For Medical Devices Coming Soon
- Pa. Justices Slam State's $80M Drug Overpayment Award
- Gordon & Rees Adds Enviro, Toxic Tort Partner In NY
- Heller Ruling May Be Knockout Punch Against Jewel Claims
- Holland & Knight Adds Ex-Kirkland Partner To IP Group
- Teva Asks High Court To Ax Fed. Circ. Claim Construction Rule
- Deals Rumor Mill: Alstom, Medtronic, BP
- Valeant To Officially Launch Hostile $53B Allergan Play
- Still The Fastest Justice Anywhere
- Sideman & Bancroft Adds IP Pro From Duane Morris
- Female Powerbrokers Q&A: Proskauer's Monica Shilling
- Female Powerbrokers Q&A: Levine Sullivan's Gayle Sproul
- Ameritox Wins $15M In Millennium Drug-Testing Kickback Row
- Novartis Dodges Punitive Damages In Aredia-Zometa Suit
- CORRECTED: 'Cobra Sexual Energy' False Ad Class Wins Cert.
- Pfizer Says Nev. AG Hid Doc Destruction In Hormone Drug Suit
- Novartis Seeks Dismissal Of FCA Kickback Claims
- Lamictal Buyers Urge 3rd Circ. To Revive Pay-For-Delay Case
- UMass RNA Patent Row To Go Forward After High Court Snub
- Rader Resignation A Head Scratcher Despite Email Flap
- Jones Day Lands IP Pro From Paul Hastings In San Diego
- Merchant & Gould Dodges DQ In Patent Suit
- Dodd-Frank Shields Overseas Whistleblowers, 2nd Circ. Told
- FDA Chides Akrimax Over Weight-Loss Product Promos
- HHS May Dig In Heels On 340B Orphan Drug Rule
- 5th Circ. Continues Trend Against 'Innovator Liability'
- Medtronic Next To Try Inversion Despite Political Blowback
- Female Powerbrokers Q&A: Nexsen Pruet's Marguerite Willis
- Female Powerbrokers Q&A: Steptoe & Johnson's Flanery
- Olympus Targets ArthroCare In Poaching Suit
- 8th Circ. Boosts Medical Expert Testimony For Plaintiffs
- Biz Groups Tell NJ Justices Whistleblower Ruling Too Broad
- Rader Calls It Quits After Email To Weil Atty
- Taxation With Representation: Tax Counsel On The Deal
- Vivus Hits Actavis With Patent Suit Over Weight-Loss Drug
- Celgene Bid To Ax FCA Suit Is Premature, US Says
- Judge Told NJ Punitive Curbs Don't Apply To Risperdal Suits
- Takeaways From Fed Circ. Opinions In Roche V. Apotex
- Ackman Brings Allergan To Court Over Poison Pill
- Female Powerbrokers Q&A: Sterne Kessler's Eldora Ellison
- Female Powerbrokers Q&A: Ogletree Deakins' Melissa Bailey
- GSK To Pay $22M To End Diabetic Drug Marketing Row
- Ex-Synthes Manager Breached Noncompete, Judge Says
- EU Pauses Zimmer's $13.4B Biomet Deal Over Missing Data
- Fed. Circ. Upholds Ruling Nixing BMS Hepatitis Drug Patent
- Eli Lilly Ducks Perjury Sanctions In $9B Actos Case
- Glenmark Suit Slams Ferring's Tactics Over Antidiuretic
- Adopt Value Or Be Left In The Ash Heap Of History
- Girardi Keese To Appeal GSK Avandia Fee Holdbacks
- CVS, Rite Aid Dodge Mich. False Claims Suits Over Generics
- Female Powerbrokers Q&A: Gordon & Rees' Leslie Benitez
- Female Powerbrokers Q&A: Bryan Cave's Chris Cesare
- The Rise Of Chemical Practice At ITC: 10 Considerations
- USPTO Training Memo Lacks Sound Basis In The Law
- ITC Stays Ban On Digital Data Imports In Dental Patent Suit
- Blue Cross Sues Takeda, Eli Lilly Over Actos Cancer Costs
- ACLU Fights Myriad's Bid For Cancer-Test Sales Ban
- Dietary Supplement Co. Natrol Enters Ch. 11
- NJ Groups Ask High Court To Widen Whistleblower Protections
- The Hidden Costs Of Spreadsheets In Risk Management
- Lessons For Contractors From The Medtronic Settlement
- 'Routine' Means 'Necessary' For Section 101
- FDA To Overhaul Device Office After Outside Critique
- NC Pols Nix Planned Curbs To Suits Over FDA-Approved Drugs
- Novartis Gets FCA Kickback Suit Pared Down
- Novartis Bone Drug Suit In Wrong Court, Judge Reiterates
- FDA Unveils Checklist For Generic Drug Approvals
- J&J Blasts Reconsideration Bid On Pa. Risperdal Punitives
- Female Powerbrokers Q&A: Gardere's Kim Yelkin
- Valeant Counters Allergan R&D Claims As Hostile Play Looms
- Female Powerbrokers Q&A: Proskauer's Margaret Dale
- 1st Circ. Affirms Dismissal of Abiomed Shareholder Suit
- PhRMA, BIO Seek Full Fed. Circ. Review Of Suprep Patent Row
- No Retrial For Atty Who Ran Stock Scheme With Ex-NFLer
- Generics Cos. Infringed Lysteda IP, Fed. Circ. Told
- NJ Pot Dispenser Wants Law Firm's Fee Demands Smoked
- FDA Partly Finalizes Guidance On Unique Device IDs
- Fed. Circ. Ends Sales Ban On Generic Latisse
- FDA Floats 1st Guidance On Track And Trace
- FDA Asks Court To Halt Sales By NY Diet Supplement Co.
- J&J Can't Remove Xarelto Defect Suit Out Of Philly
- PhRMA V. HHS Scales Back HRSA Rulemaking Power
- Female Powerbrokers Q&A: Thacker Martinsek's Martinsek
- Female Powerbrokers Q&A: Rutan & Tucker's Kathy Jenson
- O'Melveny Lands Deals Pro For Silicon Valley Office
- High Stakes In Ascertainability Of Low-Dollar Purchases
- Valeant, Ackman To Go Hostile As Allergan Spurns $53B Bid
- High Court Passes On Galderma's Acne Gel Patent Fight
- Cephalon Can't Boot Outside Firm From Off-Label Suit
- Anulex Escapes Off-Label Suture Suit
- LA Marijuana Shops' Equal Protection Suit Sputters Again
- 2nd Circ. Affirms Dismissal Of Adderall Pay-For-Delay Suit
- Novartis Beats Zometa Jaw Injury Row In New Jersey
- FDA Finalizes Rule On Electronic Drug Safety Reports
- Paul Hastings Adds Ex-Finnegan Henderson IP Pro
- FDA OKs Off-Label Petitions By Sidley Austin, Ropes & Gray
- Ackman Defends Gray Area Bid for Allergan
- Fed. Circ. Affirms WL Gore's Win In Heart Device IP Row
- Deals Rumor Mill: Allergan, Credit Suisse, Alitalia
- The Purpose Of Proposed Rule 37(e)
- Merck Drops $3.85B On Hep C Drug Co. Idenix
- Nautilus: A Reliable Compass In The Sea Of Indefiniteness?
- Female Powerbrokers: WhatleyKallas' Edith Kallas
- Female Powerbrokers Q&A: Michael Best's Kerryann Minton
- Don't Let Barko Bite Atty-Client, Work-Product Privileges
- K-V Investors Can't Save Suit Over Pregnancy Drug
- Pfizer Wins 3rd Straight Asbestos Case Over Quigley Products
- Rader Email To Weil Atty Not Enough To Restart Cases
- FDA Puts Limits On Reprints Of Drug Risk Research
- Diagnostic Testing Fight Puts FDA In A Pickle
- 3rd Circ. Buries Pfizer Investor Suit Over Alzheimer's Med
- EU Says Ranbaxy India Site Safe, Despite FDA Warnings
- Endo, Impax Schemed To Delay Opana Generics, Suit Says
- Pa. Appeals Court Affirms J&J Win In Fentanyl Patch Suit
- Female Powerbrokers Q&A: Husch Blackwell's Hanaway
- Female Powerbrokers Q&A: Waller's Katie Stenberg
- Omnicare: The Other Securities Case To Be Worried About
- Standing Ruling May Chill AIA Reviews By Interest Groups
- $570M Boston Sci Contract Row Shoots Back To State Court
- Glenmark Seeks Rehearing Of $16M Tarka Patent Judgment
- Genzyme Escapes Investor Class Action Over Stock Plunge
- Pisgah Labs Demands $100M In Soured Painkiller Deal
- Latham & Watkins Lures Kirkland IP Pro To Chicago Office
- Patton Boggs, Squire Sanders Health Pros Head To Jones Day
- Merck Accused Of Advertising Bogus Sunscreen SPF Claims
- Keys To Successful Legal Outsourcing
- Senate Confirms Burwell To Lead HHS
- 7th Circ. Denies GSK's Appeal In Reed Smith Atty Suicide Case
- Donor Risks With Charity Patient Assistant Programs
- Female Powerbrokers Q&A: Brown Rudnick's Louise Verrill
- Female Powerbrokers Q&A: Duval & Stachenfeld's Terri Adler
- Fed. Circ. Lets Endo Opana Patent Win Stand
- PhRMA Booted From Suit Over Maine Drug Importation Law
- AstraZeneca Asthma Med Injunction Rolled Into Merits Trial
- $1.3M Atty Fees Refused As CreAgri Patent Row Not Baseless
- Glenmark Birth Control Recall Suit Revived In Ohio Court
- Anatomy Of A Merger War: Valeant, Ackman Vs. Allergan
- ACA Doesn't Lower Cost Of Most Expensive Meds, PhRMA Says
- Fleming Wants $3M Fen-Phen Referral Fee Award Slashed
- Wolff & Samson Boosts IP Group With Greenberg Traurig Pro
- Fed. Circ. Says Consumer Group Can't Fight Stem Cell Patent
- How Bitcoin Will Bring About A Legal Practice Revolution
- SEC Drops Insider Trading Suit Against MiMedx CEO
- Deals Rumor Mill: CVC, Lenovo, Hutchison
- GSK Forks Up $105M To End States' Off-Label Marketing Suits
- Senate Puts Burwell One Step Closer To Top HHS Role
- Pregnancy Test Maker Can't Escape False Ad Suit
- Female Powerbrokers Q&A: Akerman's Mary Carroll
- Female Powerbrokers Q&A: Hanson Bridgett's Linda Klamm
- Sandoz Gets Claims Nixed In UTC's Generic Remodulin Fight
- You Say 'Insolubly Ambiguous,' I Say 'Reasonably Certain'
- Ex-Merck VP Says No Proof He Lied About Vioxx Study
- Procaps Wins Half Of Requested Atty Fees In Patheon Fight
- Anda Escapes Doc Demands In 'Pill Mill' Suit Coverage Feud
- Calif. City Must Put Medical Pot On Ballot, 9th Circ. Told
- Pa. Judge Asked To Rethink Barring Risperdal Punitives
- FDA Criticizes Quality Control At Wockhardt's US Unit
- PR Tax Credit Can Withstand Company Sales, 1st Circ. Says
- Chicago Sues Pharma Cos. Over Painkiller Marketing
- Myriad, Prometheus Pushing Life Sciences Cos. To Licensing
- How To Control Your Law Firm's Real Estate Costs
- CORRECTED: Teva to Buy Migraine Treatment Co. in $825M Deal
- 5 Insights From Nationwide Chief Legal Officer Pat Hatler
- Female Powerbrokers Q&A: Fross Zelnick's Barbara Solomon
- Countering The Surge In Cosmetic Class Actions
- Jury Convicts ArthroCare Execs In $400M Fraud Scheme
- High Court Indefiniteness Test Will Spur Rush To Nix Patents
- Lawyers Weigh In On High Court's Patent Indefiniteness Ruling
- Ex-DaVita Staffers Fight To Keep FCA Suit Alive
- Ropes & Gray Settles Malpractice Suit Over Patent Delay
- A Close Look At High Court Decision In Limelight V. Akamai
- DePuy 'Raided' Howmedica Sales Team, $3M Suit Says
- Deals Rumor Mill: Google, Cinven, Protective Life
- Creative Collaborations: Law Firms And Corporations
- FTC's Pharma Patent Regulations Upheld
- PE-Backed Sterigenics Raises Nordion Bid To $805M
- Ex-Alcon Exec Presses Justices For Benefit Denial Rules
- FDA Unveils Huge Database Of Adverse Events
- Mylan Strikes Deal With Pfizer To Sell Generic Celebrex
- Medtronic Says US Has It Wrong On Device Claim Preemption
- Roche Swings $350M Deal To Buy DNA Sequencing Co. Genia
- GSK Teams With Biotech Co. On $350M Cancer Drug Venture
- Female Powerbrokers Q&A: Sugarman Rogers' Chris Netski
- Female Powerbrokers Q&A: Benesch's Megan Mehalko
- Ackman Launches Allergan Proxy Fight Amid $53B Buyout Play
- High Court Clears Way For More Challenges To Vague Patents